Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes

OBJECTIVE: To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodium–glucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acut...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Care
Autores principales: Kahkoska, Anna R., Abrahamsen, Trine Julie, Alexander, G. Caleb, Bennett, Tellen D., Chute, Christopher G., Haendel, Melissa A., Klein, Klara R., Mehta, Hemalkumar, Miller, Joshua D., Moffitt, Richard A., Stürmer, Til, Kvist, Kajsa, Buse, John B.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Diabetes Association 2021
Materias:
Epidemiology/Health Services Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323175/
https://ncbi.nlm.nih.gov/pubmed/34135013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc21-0065
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares